Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Wyeth Research Division
Femme et Homme Max 99 ans
Wyeth Research Division of Wyeth Pharmaceuticals Inc., A Pfizer Company
MAJ Il y a 5 ans
An Open-label, Single-Arm, Phase 2 Study of Inotuzumab Ozogamicin Plus Rituximab in Subjects With Relapsed/Refractory CD22-Positive Diffuse Large B-Cell Lymphoma, Eligible for Autologous Stem Cell Transplantation
To evaluate efficacy and safety of inotuzumab ozogamicin in combination with rituximab when used as induction therapy prior to consolidation with HD chemo and aSCT in subjects with relapsed/refractory...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Wyeth Research Division of Wyeth Pharmaceuticals Inc
MAJ Il y a 5 ans
A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 75 MG AND 150 MG DOSES OF ERB-041 ON THE REDUCTION OF SYMPTOMS ASSOCIATED WITH ENDOMETRIOSIS DURING TREATMENT AND POST TREATMENT IN REPRODUCTIVE-AGED WOMEN
-To evaluate the superiority of ERB-041 relative to placebo on the relief of endometriosis-related symptoms (dysmenorrhea, pelvic pain, and deep dyspareunia) in reproductive-aged women using the Biber...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Wyeth Research Division of Wyeth Pharmaceuticals Inc
MAJ Il y a 5 ans
A 4-WEEK RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY OF THE PRELIMINARY EFFICACY, SAFETY, AND PHARMACOKINETICS OF PPM-204 ADMINISTERED ORALLY TO TREATMENT-NAÏVE SUBJECTS WITH TYPE II DIABETES MELLITUS
To determine the glucose lowering effects of PPM-204 in subjects with type 2 diabetes mellitus.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical resaearch and Development
MAJ Il y a 5 ans
A Randomized, Parallel, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 3 Oral Doses of ERB-041 in Subjects With Rheumatoid Arthritis on a Background of Methotrexate Therapy
To compare the efficacy and the safety of 3 dose levels of oral ERB-041 administered daily for 12 weeks versus palcebo in subjects with active RA who had a suboptimal response to therapy with stable d...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Wyeth Research Division of Wyeth Pharmaceuticals Inc
MAJ Il y a 5 ans
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation Estudio multicéntrico, aleatorizado, en doble ciego, controlado con placebo y de grupos paralelos, de MOA-728 subcutánea para el tratamiento del estreñimiento inducido por opiáceos
Primary: To evaluate the safety, efficacy, and tolerability of subcutaneous MOA-728 versus placebo in subjects with nonmalignant pain who have opioid-induced constipation.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Wyeth Research Division of Wyeth Pharmceuticals Inc. A Pfizer Company, Philadelphia, PA-19101, USA
MAJ Il y a 5 ans
A Randomized, Double-Blind Study Comparing the Safety and Efficacy of Once-Weekly Administration of Etanercept 50 mg, Etanercept 25 mg, and Placebo in Combination With Methotrexate in Subjects With Moderately Active Rheumatoid Arthritis Who Have Achieved an Adequate Response With Etanercept 50 mg Once Weekly and methotrexate
To compare the efficacy of the combination of etanercept 50 mg once weekly plus MTX with that of MTX monotherapy at week 88 in subjects with moderate RA who have achieved low disease activity or remis...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Wyeth Pharmaceutricals France Wyeth Research Division
MAJ Il y a 5 ans
A Randomized, Double-Blind Trial Assessing the Efficacy and Safety of Etanercept 50 mg Twice Weekly and Etanercept 50 mg Once Weekly for the Treatment of Moderate to Severe Psoriasis
To evaluate the effect of etanercept 50 mg once weekly for 24 weeks and etanercept 50 mg twice weekly for 12 weeks followed by etanercept 50 mg once weekly for 12 weeks in treating the skin manifestat...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Wyeth Pharmaceuticals France, Wyeth Research Division
MAJ Il y a 5 ans
A phase II a , Multicenter, Randomized , Third -party Unblinded , Long- term Extension study to Determine Safety, Tolerability and Immunogenicity of ACC-001 with and without QS21 Adjuvant in Subjects with Mild to Moderate Alzheimzer's Disease Estudio de fase IIa, multicéntrico, aleatorizado y con tercera parte conocedora del tratamiento, de extensión a largo plazo, para determinar la seguridad, la tolerabilidad y la inmunogenicidad de ACC-001, con y sin adyuvante QS-21, en sujetos con enfermedad de Alzheimer de grado leve a moderado
The primary objective of the study is to evaluate the long-term safety and tolerability of doses of 3, 10, and 30 µg of ACC-001 (CRM-conjugated A-beta [1-7] antigen alone and in combination with QS-21...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Wyeth Research Division of Wyeth Pharmaceuticals Inc
MAJ Il y a 5 ans
A Phase 2, Randomized, Open-label Study of Bosutinib Administered in Combination With Letrozole Versus Letrozole Alone as First Line Therapy in Post-Menopausal Women With Locally Advanced or Metastatic ER+/PgR+/erbB2- Breast Cancer
To compare the efficacy, in terms of PFS assessed by an independent radiology vendor, of bosutinib in combination with letrozole versus letrozole alone as first line treatment or as recurrence of adju...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Wyeth Research Division of Wyeth Pharmaceuticals Inc
MAJ Il y a 5 ans
A Multicenter, Randomized, Double-Blind, Comparison Study of the Safety and Efficacy of a Once-Daily Dose of Tigecycline versus Ertapenem for the Treatment of Foot Infections in Subjects with Diabetes
To compare the relative safety and clinical efficacy of a once-daily dose of tigecycline versus ertapenem in the treatment of subjects with diabetic foot infections.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
4
5
6
7
8
9
Suivant